3 results
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.
Study Stage 1:To evaluate the safety and tolerability of BaroFeron administered subcutaneously (SC)To determine the PK and PD profiles of BaroFeron administered SC and compare to Betaferon administered SCTo evaluate evidence of activity of BaroFeron…
The objective of the study is to asses the efficacy and safety of intravenous ATB200 co-administration with oral AT2221 by evaluating the changes in key clinical outcome measures (eg, motor, respiratory, fatigue) in adult subjects with late-onset…